Analysts Set Expectations for Immunovant FY2025 Earnings

Immunovant, Inc. (NASDAQ:IMVT - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Immunovant in a research report issued to clients and investors on Tuesday, March 4th. Cantor Fitzgerald analyst P. Agrawal expects that the company will post earnings per share of ($1.88) for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Immunovant's current full-year earnings is ($2.69) per share. Cantor Fitzgerald also issued estimates for Immunovant's FY2026 earnings at ($2.92) EPS.

A number of other brokerages also recently weighed in on IMVT. Bank of America lowered their target price on shares of Immunovant from $48.00 to $45.00 and set a "buy" rating on the stock in a research note on Wednesday, January 15th. Wolfe Research cut shares of Immunovant from an "outperform" rating to a "peer perform" rating in a research report on Friday, January 3rd. HC Wainwright reiterated a "buy" rating and issued a $51.00 target price on shares of Immunovant in a research report on Friday, February 7th. Jefferies Financial Group started coverage on Immunovant in a research report on Monday, March 3rd. They set a "hold" rating and a $20.00 price target on the stock. Finally, Wells Fargo & Company dropped their price target on Immunovant from $47.00 to $45.00 and set an "overweight" rating for the company in a research note on Thursday, December 19th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Immunovant presently has an average rating of "Buy" and an average price target of $43.55.

Remove Ads

Immunovant Price Performance

Shares of NASDAQ:IMVT traded up $0.28 on Thursday, hitting $20.30. The company's stock had a trading volume of 1,227,116 shares, compared to its average volume of 1,242,054. The company has a market capitalization of $3.45 billion, a PE ratio of -7.75 and a beta of 0.68. The company has a 50-day simple moving average of $21.85 and a 200 day simple moving average of $26.48. Immunovant has a 1 year low of $17.65 and a 1 year high of $35.97.

Immunovant (NASDAQ:IMVT - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.08).

Institutional Investors Weigh In On Immunovant

Large investors have recently made changes to their positions in the business. KBC Group NV lifted its stake in Immunovant by 46.2% in the third quarter. KBC Group NV now owns 1,936 shares of the company's stock worth $55,000 after acquiring an additional 612 shares during the period. Assetmark Inc. lifted its position in shares of Immunovant by 73.8% in the 3rd quarter. Assetmark Inc. now owns 2,891 shares of the company's stock worth $82,000 after purchasing an additional 1,228 shares during the period. GF Fund Management CO. LTD. purchased a new stake in shares of Immunovant in the 4th quarter worth about $76,000. Ameriprise Financial Inc. bought a new stake in shares of Immunovant during the 4th quarter valued at about $221,000. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of Immunovant during the fourth quarter valued at about $268,000. 47.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Peter Salzmann sold 5,105 shares of the firm's stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $24.10, for a total value of $123,030.50. Following the sale, the chief executive officer now directly owns 972,992 shares of the company's stock, valued at $23,449,107.20. This trade represents a 0.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CTO Jay S. Stout sold 2,195 shares of the company's stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $23.59, for a total value of $51,780.05. Following the transaction, the chief technology officer now directly owns 139,991 shares of the company's stock, valued at $3,302,387.69. The trade was a 1.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 27,510 shares of company stock worth $656,886 in the last ninety days. 5.90% of the stock is owned by insiders.

About Immunovant

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.